Q3 2014 13F Holders as of 30 Sep 2014
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
130,702,820
-
Number of holders
-
8
-
Total 13F shares, excl. options
-
6,016,277
-
Shares change
-
+6,016,277
-
Total reported value, excl. options
-
$19,267,000
-
Value change
-
+$19,267,000
-
Number of buys
-
8
-
Price
-
$3.20
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q3 2014
8 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q3 2014.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 8 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6,016,277 shares
of 130,702,820 outstanding shares and own 4.6% of the company stock.
Largest 9 shareholders include NEA Management Company, LLC (2,546,843 shares), GREAT POINT PARTNERS LLC (2,474,076 shares), BAKER BROS. ADVISORS LP (727,669 shares), DEUTSCHE BANK AG\ (133,333 shares), Cheyne Capital Management (UK) LLP (106,805 shares), ROYAL BANK OF CANADA (13,451 shares), BANK OF MONTREAL /CAN/ (12,500 shares), Tower Research Capital LLC (1,600 shares), and Ground Swell Capital, LLC (500 shares).
This table shows the top 8 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.